Department of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, Hebei Province, China.
The Cancer Institute, Tangshan People's Hospital, Tangshan, Hebei Province, China.
Medicine (Baltimore). 2022 Sep 9;101(36):e30239. doi: 10.1097/MD.0000000000030239.
Vulvar melanoma is a rare and aggressive tumor with a high risk of local recurrence and distant metastasis. The prognosis is poor with a 5-year overall survival rate of only 46.6%. Management of vulvar melanoma remains a clinical challenge. Recent evidences have shown that immune checkpoint inhibitors are effective in the treatment of vulvar melanoma.
A 63-year-old woman with vulvar malignant melanoma suffered inguinal lymph node metastasis after vulvectomy and chemotherapy. She underwent inguinal lymph node dissection and inguinal radiotherapy. The tumor progressed again and she received immunotherapy.
The tumor progressed again, and she was admitted to our hospital and received toripalimab combined with apatinib and abraxane.
After 6 cycles of immunotherapy, the efficacy achieved partial remission. And with toripalimab as maintenance therapy, the patient achieved durable antitumor efficacy and good safety.
In this rare case, the patient with metastatic vulvar malignant melanoma had durable antitumor efficacy and good safety when receiving toripalimab.
外阴黑色素瘤是一种罕见且侵袭性强的肿瘤，局部复发和远处转移风险高。预后较差，5 年总生存率仅为 46.6%。外阴黑色素瘤的治疗仍然是临床挑战。最近的证据表明，免疫检查点抑制剂在治疗外阴黑色素瘤方面有效。
一位 63 岁女性，外阴恶性黑色素瘤患者，在外阴切除术和化疗后发生腹股沟淋巴结转移。她接受了腹股沟淋巴结清扫术和腹股沟放疗。肿瘤再次进展，她接受了免疫治疗。
肿瘤再次进展，她被收入我院并接受特瑞普利单抗联合阿帕替尼和白蛋白紫杉醇治疗。
免疫治疗 6 个周期后，疗效达到部分缓解。并使用特瑞普利单抗作为维持治疗，患者获得了持久的抗肿瘤疗效和良好的安全性。
在这例罕见病例中，转移性外阴恶性黑色素瘤患者接受特瑞普利单抗治疗具有持久的抗肿瘤疗效和良好的安全性。
